Member LoginDividend CushionValue Trap
|
Valuentum
Reports
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Jan 19, 2017
The Dreaded Patent Cliff: 3 Pharmaceutical Companies at Risk
Image Source: Global Panorama. Let's have a look at 3 pharmaceutical giants that may encounter some troubles in coming years. Jan 6, 2017
CVS Health In The Bargain Bin? We Think So
Image Source: Mike Mozart. We are adding CVS Health to the newsletter portfolios. Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins. Oct 31, 2016
Dividend Increases/Decreases for the Week Ending October 28
Let's take a look at companies raising/lowering their dividends this week. Oct 26, 2016
EVERYTHING DIVIDENDS + 3 TOP IDEAS
The Valuentum analyst team explains the difference between the adjusted Dividend Cushion ratio and its unadjusted counterpart. The success of the Dividend Growth Newsletter portfolio is covered, and Valuentum's top 3 dividend growth ideas are unveiled. ~13 minutes. Aug 10, 2016
Oncology News a Key Driver of Big Pharma
Image Source: Images Money. Oncology product portfolios and pipelines have been key factors in the big pharma industry as of late. May 17, 2016
Big Pharma 1Q Earnings Roundup, Part II
Image Source: Paw Paw. Let’s take a look at the first quarter performance and some major news for some of the biggest players in the pharmaceuticals sector. Included in this article: ABBV, AGN, BMY, AMGN, MRK, PFE. May 2, 2016
Gilead: What's Your Long Term Thesis?
Image Source: Gilead. We’re starting to see some even bigger risks at Gilead – long-term ones. May 2, 2016
April Deals May Flower Future Growth
Image Source: Iqbal Osman. A series of mergers and acquisitions were announced in late April. Will the wave of deal making provide too big a shock to acquirers, or will their future growth trajectories flower? Let’s take a quick look at some of the deals and their impact on the companies involved. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
Image Source: kennijima. Bristol-Myers Squibb has seen its shares fall to $50 from nearly $80 in just the past few months as clinical outcomes of its crucial product Opdivo have come under fire. Have shares finally found support? Let’s have a look.